STOCK TITAN

Ocuphire Pharma to Present in the BIO CEO & Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Ocuphire Pharma, Inc. (OCUP) CEO to Present Company Overview at BIO CEO & Investor Conference in New York City. The presentation will focus on the development and commercialization of small-molecule therapies for retinal and refractive eye disorders.
Positive
  • None.
Negative
  • None.

FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A, M.S. CEO of Ocuphire, will be presenting a company overview at the BIO CEO & Investor Conference being held February 26-27 2024 in New York City. Company management will also be participating in one-on-one meetings throughout the conference.

BIO CEO & Investor Conference – February 26-27, 2024
Title:  Ocuphire Pharma, Inc. (OCUP) Company Presentation
Presenter:  George Magrath, M.D. M.B.A, M.S.
Date:  Tuesday, February 27, 2024
Time:  2:45 – 3:00pm ET
Location:  Plymouth Room, Marriott Marquis, New York, NY


If you are interested in arranging a 1x1 meeting, please contact your conference representative or send an email to ir@ocuphire.com. For more details, please see the Investors and Events section of Ocuphire’s corporate website.

About Ocuphire Pharma

Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders.

Ocuphire’s lead retinal product candidate, APX3330, is a first-in-class small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref-1 is a regulator of the transcription factors HIF-1α and NF-κB. Inhibiting REF-1 reduces levels of vascular endothelial growth factor (“VEGF”) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. Through inhibition of Ref-1, APX3330 normalizes the levels of VEGF to physiologic levels, unlike biologics that deplete VEGF below the levels required for normal function. APX3330 is an oral tablet to be administered twice per day for the treatment of diabetic retinopathy (“DR”). A Phase 2 study in subjects with DR and an End-of-Phase 2 meeting have recently been completed, and a Special Protocol Assessment (“SPA”) is planned to be submitted to the FDA.

DR affects approximately 10 million people with diabetes and is projected to impact over 14 million Americans by 2050. DR is classified as Non-Proliferative Diabetic Retinopathy (“NPDR”), the early stage of the disease in which symptoms may be mild or non-existent or Proliferative Diabetic Retinopathy (“PDR”) which is the more advanced stage of diabetic eye disease that can be highly symptomatic with loss of vision. Approximately 8 million patients with DR have NPDR that will progress to PDR if left untreated. Despite the risk for visual loss associated with this disease, over 90% of NPDR patients currently receive no course of treatment apart from observation by their eye care specialist until they develop sight-threatening complications. This is due to the treatment burden of the frequent eye injections required with currently approved therapies for this disease. APX3330 as an oral tablet has the potential to be an early, non-invasive treatment for the 8 million NPDR patients in the U.S. Treatment with APX3330 is expected to delay or prevent progression of NPDR, thereby reducing the need for expensive intravitreal injections with anti-VEGF therapies and reducing the likelihood of vision loss due to DR.

Ocuphire has also in-licensed APX2009 and APX2014, which are second-generation analogs of APX3330. The unique mechanism of action of these Ref-1 inhibitors that reduces both angiogenesis and inflammation could potentially be beneficial in treating other retinal diseases such as age-related macular degeneration and geographic atrophy. Ocuphire is currently evaluating local delivery routes in addition to the systemic (oral) route as part of its pipeline expansion in retinal therapies.

Ocuphire also has a partnership with Viatris, Inc. to develop and commercialize phentolamine ophthalmic solution 0.75%. Phentolamine is a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size by uniquely blocking the alpha-1 receptors found on the iris dilator muscle without affecting the ciliary muscle. In September 2023, the FDA approved RYZUMVI™ (phentolamine ophthalmic solution 0.75%) to treat pharmacologically induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic agents (e.g., tropicamide). Phentolamine ophthalmic solution 0.75% is also in Phase 3 clinical development for the treatment of presbyopia and for the treatment of decreased visual acuity in dim (mesopic or low) light conditions after keratorefractive surgery.

For more information, visit www.ocuphire.com

Contacts

Corporate Investor Relations 
George Magrath, M.D., M.B.A., M.S.
CEO
ir@ocuphire.com 
Corey Davis, Ph.D. 
LifeSci Advisors 
cdavis@lifesciadvisors.com


FAQ

When is the BIO CEO & Investor Conference being held?

The BIO CEO & Investor Conference is being held on February 26-27, 2024 in New York City.

Who will be presenting the company overview at the conference?

George Magrath, M.D. M.B.A, M.S, the CEO of Ocuphire Pharma, Inc., will be presenting the company overview.

What is the focus of Ocuphire Pharma, Inc. in terms of drug development?

Ocuphire Pharma, Inc. is focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders.

Where will the company presentation take place?

The company presentation will take place in the Plymouth Room at Marriott Marquis, New York, NY.

How can one arrange a 1x1 meeting with Ocuphire Pharma, Inc. during the conference?

To arrange a 1x1 meeting, interested individuals can contact their conference representative or send an email to ir@ocuphire.com.

Ocuphire Pharma, Inc.

NASDAQ:OCUP

OCUP Rankings

OCUP Latest News

OCUP Stock Data

30.65M
24.19M
6.11%
8.7%
3.55%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FARMINGTON HILLS